Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

Review Compares Psoriasis Therapies in Asian Populations

Review insights from a premier dermatology event with expert sessions, hands-on insights, and networking to elevate clinical practice.

Elevate-Derm West Conference 2024 Recap

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

The LIBERO study confirmed brodalumab is effective in managing psoriasis in patients over 100 kg, showing comparable long-term benefits in patients under 100 kg.

Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

Reviewing Multiple Subtypes of CHE and Delgocitinib as a Pan-JAK Inhibitor

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Managing Vitiligo: Case Studies and Community Treatment Perspectives

Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

Videos

Pearl E. Grimes, MD,discusses managing long-standing vitiligo through various strategies, including combination therapies for stabilization and repigmentation, OTC solutions for facial involvement, and the evolving role of FDA-approved topical ruxolitinib in redefining treatment paradigms.

Pearl E. Grimes, MD, provides case-based insights on managing long-standing vitiligo with extensive depigmentation and atopic comorbidities, focusing on treatment history, comorbid conditions, and the impact on quality of life.

Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

Pearl E. Grimes, MD, discusses strategies for optimizing vitiligo stabilization and repigmentation through combination therapies, emphasizing long-term maintenance, treatment modalities, and the use of topical agents like tacrolimus and ruxolitinib cream.




Pearl E. Grimes, MD, explores managing long-standing vitiligo with facial involvement, focusing on over-the-counter solutions, repigmentation strategies, and relapse prevention techniques.



Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.


Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

Case Based Peer Perspectives

Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP: 1.Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

EP: 2.Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP: 3.Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP: 4.Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm